Review
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 765-793
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.765
Table 1 Artificial intelligence applications in the prevention of hepatocellular carcinoma

First author
Parameters employed
AI classifier
Sizes of the training/validation sets
Outcomes
Performance
Ref.
1Wang JGenetic and epigenetic biomarkersSeveral137 HCC and 431 non-HCC patientsHCC screening0.910-0.9501,2, 0.897-0.9381,3, 75.0-91.52,4, 66.4-90.63,4, 1.0-88.82,5, 0.5-87.93,5[47]
2Nam JYLaboratory results, clinicopathological parametersDNN424/3163 patientsHCC development in HBV cirrhosis0.7191,2, 0.7821,3[48]
3Xia QLong non-coding RNAsSeveral38 healthy samples, 45 chronic HBV patients, 46 liver cirrhosis, and 46 HCC patientsHCC development in HBV cirrhosis71.1-89.53,6[49]
4Chen SHBV reverse transcriptase gene sequencingRF, SVM, KNN307 chronic HBV patients (202/105), 237 HCC patients (159/78)HCC development in HBV cirrhosisRF: 0.902-0.9031,2, 0.903-0.9431,3, SVM: 0.879-0.9241,2, 0.727-0.8581,3, KNN: 0.680-0.7371,2, 0.734-0.7471,3[50]
5Hashem SLaboratory results, clinicopathological parametersSeveral3099 chronic HCV patients1324 HCC patientsHCC development in HCV cirrhosis93.2-95.63,6, 0.955-0.9901,3, 86.3-91.83,4, 93.9-97.33,5[51]
6Audureau ELaboratory results, clinicopathological parametersSeveral836/6687HCC development in HCV cirrhosis0.633-0.8071,2, 0.623-0.7151,7[52]
7Ioannou GNClinical/laboratory data extracted directly from electronic health recordsDNN48151 patients with HCV-related cirrhosis (training:test = 9:1)HCC development in HCV cirrhosis0.759-0.8061,3[53]
8Singal AGLaboratory results, clinicopathological parametersRF442/10507HCC development in cirrhosis0.711,2, 0.641,7[54]